Skip to content

Psilocybin and psychedelic-assisted therapy: all studies

Page 4 of 25: studies 31 to 40 of 248, newest first. Back to the psilocybin and psychedelic-assisted therapy overview

Research

A qualitative analysis of participant expectations and experiences of psilocybin‐assisted psychotherapy for methamphetamine use disorder

Addiction December 22, 2025 Jonathan Brett, Toby Lea, Elizabeth Knock et al.

Abstract Background and aims There is an urgent unmet need for novel treatments for methamphetamine (MA) use disorder. We explored the qualitative experiences of people participating in a study of psilocybin‐assisted psychotherapy (PAT) to treat MA use disorder. Design and setting Qualitative study of participants enrolled in a single arm, open‐label pilot study of PAT for MA use disorder...

DOI: 10.1111/add.70284 (opens in new tab) Qualitative research Qualitative analysis Interpersonal communication Focus group +7

Psilocybin-assisted psychotherapy for treatment-resistant obsessive–compulsive disorder: protocol for an open-label pilot study

BJPsych Open December 15, 2025 Nicole Ledwos, Jenna Baer, Muhammad Ishrat Husain et al. 2 citations

Background Obsessive–compulsive disorder (OCD) is a debilitating mental disorder commonly treated with selective serotonin reuptake inhibitors, atypical antipsychotic augmentation and cognitive–behavioural therapy. However, up to 60% of people with OCD do not respond to these treatments. Therefore, a novel intervention, psilocybin-assisted psychotherapy (PAP), is an option of interest....

DOI: 10.1192/bjo.2025.10895 (opens in new tab) Protocol science Pilot trial Field mathematics Research design +2

Investigational psilocybin treatment for post-traumatic stress disorder: a qualitative study of participant experience, trauma engagement, and differences from standard treatment.

EClinicalMedicine December 1, 2025 Nadav Liam Modlin, Victoria Williamson, Guy M. Goodwin et al. 2 citations

Post-traumatic stress disorder (PTSD) is a debilitating condition leading to significant personal and societal burden. Standard treatments frequently demonstrate limited efficacy, leading to persistent symptoms and high dropout rates. Psilocybin has shown promise in treating depression, a condition that is often comorbid with PTSD. We aimed to explore participant experiences of psilocybin...

Psychedelics as a Therapeutic Opportunity or Threat: A Narrative Review.

Cureus December 1, 2025 Paweł Liszka, Agata Ogórek, Klaudia M Olejnik-Chlewicka et al.

Classic psychedelics and related substances, such as 3,4-methylenedioxymethamphetamine (MDMA), have again become a focus of interest in psychiatry as potential therapeutic tools. The aim of this paper is to review current data on their mechanisms of action, clinical applications in the treatment of mood and anxiety disorders, addictions and post-traumatic stress disorder (PTSD), as well as to...

Hormonal Influences on Psilocybin Responsivity Across the Female Lifespan: Toward Personalized Psychedelic-Assisted Therapy

Psychoactives November 2, 2025 Faith Ekoh, Shanice Rerrie, James Angud et al. 2 citations

Today’s research highlights the therapeutic potential of the hallucinogen psilocybin in the treatment of pathologies associated with mood, cognitive, and affective dysregulation. These domains of function are regulated by the serotonergic system, which can be influenced by sex hormones, like estrogen and testosterone, and psychedelic compounds including psilocybin. Current evidence supports a...

Reporting of side-effects in clinical trials of psilocybin-assisted psychotherapy for psychiatric conditions: systematic review

BJPsych Open November 1, 2025 Jonathon Marinis, Sarah Clarke, Alexandre A. Guerin et al. 2 citations

Background Psilocybin-assisted psychotherapy (PAP) has gained attention as a promising intervention for conditions including depression, anxiety and post-traumatic stress disorder, but understanding of its side-effects is limited. This review evaluates the quality of side-effects reporting in PAP trials, to guide treatment, policy and research. Aims To assess side-effects reporting quality in...

DOI: 10.1192/bjo.2025.10847 (opens in new tab) Clinical trial Medline Systematic review Alternative medicine +2

Provider perspectives on challenges in treatment during psychedelic therapy.

Psychopharmacology October 27, 2025 David A Bender, Sandeep M. Nayak, Joshua S. Siegel et al.

Psychedelic treatments are considered to involve unique treatment challenges relative to other psychiatric interventions, though these are typically not explored in detail within clinical trial reports. To determine the types of challenges that providers encounter while administering psychedelic drugs in research settings and to assess provider opinions on safeguards that may be pursued to...

Psilocybin-assisted psychotherapy in adults with depression – A literature review

Progress in Neuro-psychopharmacology and Biological Psychiatry September 24, 2025 Marie Celine Dorczok, Gloria Mittmann, Thomas Ettl et al. 2 citations

PAP combined with structured psychological support shows sustained reductions in depressive symptoms for treatment-resistant depression and major depressive disorder. Higher doses generally yield stronger benefits. While PAP holds significant potential as a holistic treatment, methodological limitations, such as heterogeneity in study designs, inconsistent levels of psychological support and...

Psilocybin‐assisted psychotherapy for methamphetamine use disorder: A pilot open‐label safety and feasibility study

Addiction September 20, 2025 Elizabeth Knock, Krista J. Siefried, Gillinder Bedi et al. 4 citations

Abstract Background & Aims There are few effective treatments for methamphetamine use disorder, despite increasing global demand. Here, we assessed the safety and feasibility of outpatient psilocybin‐assisted psychotherapy for methamphetamine use disorder. Design Single arm, open label pilot study. Setting Outpatient public stimulant treatment program at St. Vincent's Hospital, Sydney,...

Why psychedelic-assisted therapy studies in eating disorders risk missing the mark on outcomes: a phenomenological psychopathology perspective.

Journal of Eating Disorders September 2, 2025 Elena Koning, Riccardo Miceli Mcmillan, Aaron Keshen et al. 3 citations

Psychedelic-assisted therapy (PAT) is an emerging intervention in psychiatry, for which there is preliminary evidence for effectiveness in eating disorders (EDs). The subjective psychedelic experience is considered an important driver of positive outcomes following PAT; however, conventional study design approaches often overlook many of the nuances inherent to the experience. Consequently,...